Jaguar Health Seeks Approval for Up to 1-for-150 Reverse Split and Massive Dilution
JAGX sits 17% above its 52-week low of $2.35 on elevated volume (8.2× avg).
Summary
Jaguar Health filed a preliminary proxy for an October 23 special meeting seeking approval for a reverse split up to 1-for-150, a lower ELOC floor price, and warrant exercises that could make Joshua Mailman the largest shareholder.
Key Events · Corporate Governance and Compliance · JAGX
-
Reverse Split Up to 1-for-150
Proposal 4 seeks board discretion to effect a reverse split between 1-for-2 and 1-for-150. At the maximum ratio, the 520,140 outstanding shares would become approximately 3,468 shares.
-
ELOC Floor Price Cut
Proposal 5 would reduce the C/M Capital equity line floor price from $16.50 to an unspecified lower amount. At today's $2.76 price, the current floor makes the ELOC unusable; lowering it enables sales at current market prices.
-
Mailman Could Become Largest Shareholder
Proposal 6 would allow Joshua Mailman and affiliates to exercise warrants for 149,888 shares, bringing their total ownership to approximately 27.8% of outstanding shares — the largest position.
-
Series Q Exchange Could Add 4.7M Shares
Proposal 1 seeks approval for exchange of Series Q Preferred Stock into up to 4,689,923 shares post-split, representing approximately 53.5% of current outstanding shares at a $2.50 exchange price.
Analysis · JAGX · Life Sciences
Jaguar Health is asking shareholders to approve a package of highly dilutive actions at an October 23 special meeting. The most extreme is a reverse stock split of up to 1-for-150, which would shrink the float to roughly 3,500 shares from 520,140. The company also wants to cut the ELOC floor price from $16.50 to an unspecified lower level, enabling C/M Capital to buy shares at today's $2.76 price. Separately, Joshua Mailman and his affiliates could acquire up to 27.8% of the company through warrant exercises, making him the largest shareholder. The company has $3.8M in cash and a going concern warning, so these approvals are about survival — but existing shareholders face extreme dilution.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 48.6% of the 216 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.05%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $2.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $933.7K. The 52-week trading range was $2.35 to $1,280.95. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.